Dermatomyositis
Polymyositis Inclusion
Body Myositis
Systemic Lupus Erythematosus
If your insurance is not listed, please call our office if you have questions regarding your insurance coverage. If you have out-of-network benefits, then your insurance may reimburse you for a portion of your office visit. We will work with you and your insurance to minimize your out-of-pocket costs. Financial assistance may be available for patients in need.
Attending Physician, Hospital for Special Surgery
American Board of Internal Medicine - Internal Medicine
American Board of Internal Medicine - Rheumatology
Lupus and Antiphospholipid Syndrome Center of Excellence Research Fund Award, 2016
F31 Predoctoral Fellowship, NIAMS, 2008-201
SUNY Upstate Medical University, Syracuse
NewYork-Presbyterian - Weill Cornell Medical Center, New York
NewYork-Presbyterian - Weill Cornell Medical Center, New York
Hospital for Special Surgery, New York
English, Spanish
For all publications, please see the PubMed listing.
Currently studying the role of cell-free mitochondrial DNA in triggering interferon production and disease flares in patients with systemic lupus erythematosus, as well as the effect of medications used to treat lupus patients on mitochondrial DNA release.
Additionally, working to identify clinical features in a large cohort of lupus patients that may allow us to better define subgroups of patients.
HSS has a long history of supporting appropriate relationships with industry because they advance HSS's mission to provide the highest quality patient care, improve patient mobility, and enhance the quality of life for all, and to advance the science of orthopedic surgery, rheumatology, and their related disciplines through research and education.
As of May 11, 2024, Dr. Fernandez reported no relationships with the healthcare industry.
HSS and its physicians make this information available to patients and the public, thus creating a transparent environment for those who are interested in this information. Further, the HSS Conflicts of Interest and Commitment Policy prohibits physicians from collecting royalties on products they develop that are used on patients at HSS.
